Patient characteristics
| Characteristic . | Result . |
|---|---|
| No. of patients | 47 |
| Median age, y (range) | 53 (33-68) |
| Sex, no. (%) | |
| Male | 25 (53) |
| Female | 22 (47) |
| Chemotherapies before transplantation (%) | |
| Rituximab-chemo combinations | 35 (74) |
| 3 regimens | 7 (15) |
| 4 regimens | 12 (25.5) |
| >5 regimens | 5 (10.5) |
| No. of patients with prior autologous transplantation (%) | 9 (19) |
| Additional therapies before transplantation (%) | |
| Radio-immunotherapy | 1 |
| Rituximab, single agent | 13 (28) |
| Total lymphoid irradiation | 1 |
| Localized radiation | 11 (23) |
| Interferon | 7 (15) |
| Other investigational agents | 4 (8) |
| International Prognostic Index score at study entry, median (range) | 1 (0-3) |
| Grade, no. (%) | |
| 1 or 2 | 37 (79) |
| 3 | 10 (21) |
| Median time from diagnosis to transplantation, y (range) | 3 (0.7-24) |
| Disease status at transplantation, no (%) | |
| Complete remission | 18 (38) |
| Partial remission | 29 (62) |
| Stem cell source, no (%) | |
| Marrow/blood | 2 (4)/45 (96) |
| Related/unrelated donor | 45 (96)/2 (4) |
| CD34-positive cell infused, ×106/kg, median (range) | 4.5 (3-7) |
| Characteristic . | Result . |
|---|---|
| No. of patients | 47 |
| Median age, y (range) | 53 (33-68) |
| Sex, no. (%) | |
| Male | 25 (53) |
| Female | 22 (47) |
| Chemotherapies before transplantation (%) | |
| Rituximab-chemo combinations | 35 (74) |
| 3 regimens | 7 (15) |
| 4 regimens | 12 (25.5) |
| >5 regimens | 5 (10.5) |
| No. of patients with prior autologous transplantation (%) | 9 (19) |
| Additional therapies before transplantation (%) | |
| Radio-immunotherapy | 1 |
| Rituximab, single agent | 13 (28) |
| Total lymphoid irradiation | 1 |
| Localized radiation | 11 (23) |
| Interferon | 7 (15) |
| Other investigational agents | 4 (8) |
| International Prognostic Index score at study entry, median (range) | 1 (0-3) |
| Grade, no. (%) | |
| 1 or 2 | 37 (79) |
| 3 | 10 (21) |
| Median time from diagnosis to transplantation, y (range) | 3 (0.7-24) |
| Disease status at transplantation, no (%) | |
| Complete remission | 18 (38) |
| Partial remission | 29 (62) |
| Stem cell source, no (%) | |
| Marrow/blood | 2 (4)/45 (96) |
| Related/unrelated donor | 45 (96)/2 (4) |
| CD34-positive cell infused, ×106/kg, median (range) | 4.5 (3-7) |